{"id":"autologous-engineered-skin-substitute","safety":{"commonSideEffects":[{"rate":"null","effect":"Wound infection"},{"rate":"null","effect":"Skin graft rejection"}]},"_chembl":{"chemblId":"CHEMBL2108643","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment involves taking a patient's own skin cells, expanding them in a laboratory, and then reapplying them to the affected area to stimulate the growth of new skin tissue. The goal is to create a functional skin substitute that can help repair damaged skin and promote wound healing.","oneSentence":"Autologous Engineered Skin Substitute is a regenerative medicine that uses a patient's own cells to promote skin healing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:49.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Burns, wounds, and other skin injuries"}]},"trialDetails":[{"nctId":"NCT03227146","phase":"PHASE2","title":"Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"CUTISS AG","startDate":"2017-10-25","conditions":"Burns","enrollment":14},{"nctId":"NCT03229564","phase":"PHASE2","title":"Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"CUTISS AG","startDate":"2017-10-25","conditions":"Burns","enrollment":12},{"nctId":"NCT03394612","phase":"PHASE2","title":"Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"CUTISS AG","startDate":"2018-02-14","conditions":"Skin Wound","enrollment":20},{"nctId":"NCT06745557","phase":"PHASE3","title":"Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents","status":"RECRUITING","sponsor":"CUTISS AG","startDate":"2024-12-13","conditions":"Burns","enrollment":70},{"nctId":"NCT05234658","phase":"PHASE2","title":"Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery","status":"UNKNOWN","sponsor":"Andalusian Network for Design and Translation of Advanced Therapies","startDate":"2022-01-21","conditions":"Basal Cell Carcinoma","enrollment":21},{"nctId":"NCT02145130","phase":"PHASE1","title":"Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-05","conditions":"Burn Injury, Soft Tissue Injury, Skin Necrosis","enrollment":12},{"nctId":"NCT01655407","phase":"PHASE2","title":"Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds","status":"UNKNOWN","sponsor":"Amarantus BioScience Holdings, Inc.","startDate":"2016-09","conditions":"Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn","enrollment":10},{"nctId":"NCT00207818","phase":"PHASE1, PHASE2","title":"Treatment of Cutaneous Ulcers With a Novel Biological Dressing","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"1999-09","conditions":"Venous Ulcers","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ESS-W"],"phase":"phase_2","status":"active","brandName":"Autologous Engineered Skin Substitute","genericName":"Autologous Engineered Skin Substitute","companyName":"Amarantus BioScience Holdings, Inc.","companyId":"amarantus-bioscience-holdings-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous Engineered Skin Substitute is a regenerative medicine that uses a patient's own cells to promote skin healing. Used for Burns, wounds, and other skin injuries.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}